Merit medical announces positive results in first-in-human study of wrapsody™ cell-impermeable endoprosthesis

Prospective, observational study published in cardiovascular and interventional radiology 1 reports 100% target lesion primary patency (“tlpp”) rate without reintervention through 30 days, with a 12-month tlpp rate of 84.6% and a 12-month access circuit primary patency (“acpp”) rate of 65.9%.
MMSI Ratings Summary
MMSI Quant Ranking